ThermoGenesis - THMO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.00
  • Forecasted Upside: 294.94 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.25
▲ +0.0078 (3.18%)

This chart shows the closing price for THMO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ThermoGenesis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for THMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for THMO

Analyst Price Target is $1.00
▲ +294.94% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ThermoGenesis in the last 3 months. The average price target is $1.00, with a high forecast of $1.00 and a low forecast of $1.00. The average price target represents a 294.94% upside from the last price of $0.25.

This chart shows the closing price for THMO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in ThermoGenesis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/12/2022HC WainwrightLower TargetBuy$6.00 ➝ $1.00Low
11/15/2021HC WainwrightReiterated RatingBuy$6.00Low
3/18/2021HC WainwrightReiterated RatingBuy$8.50 ➝ $6.00Medium
11/13/2020HC WainwrightLower TargetBuy$9.50 ➝ $8.50Medium
4/17/2020HC WainwrightBoost TargetSell ➝ Buy$7.00 ➝ $9.50Low
11/21/2019HC WainwrightReiterated RatingBuy$7.50High
(Data available from 8/18/2017 forward)

News Sentiment Rating

-0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/20/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/19/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/20/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/19/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/18/2022

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
ThermoGenesis logo
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
Read More

Today's Range

Now: $0.25
Low: $0.24
High: $0.26

50 Day Range

MA: $0.26
Low: $0.18
High: $0.37

52 Week Range

Now: $0.25
Low: $0.09
High: $2.50

Volume

57,383 shs

Average Volume

2,987,577 shs

Market Capitalization

$3.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.8

Frequently Asked Questions

What sell-side analysts currently cover shares of ThermoGenesis?

The following Wall Street research analysts have issued reports on ThermoGenesis in the last year: HC Wainwright.
View the latest analyst ratings for THMO.

What is the current price target for ThermoGenesis?

1 Wall Street analysts have set twelve-month price targets for ThermoGenesis in the last year. Their average twelve-month price target is $1.00, suggesting a possible upside of 294.9%. HC Wainwright has the highest price target set, predicting THMO will reach $1.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.00 for ThermoGenesis in the next year.
View the latest price targets for THMO.

What is the current consensus analyst rating for ThermoGenesis?

ThermoGenesis currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe THMO will outperform the market and that investors should add to their positions of ThermoGenesis.
View the latest ratings for THMO.

What other companies compete with ThermoGenesis?

How do I contact ThermoGenesis' investor relations team?

ThermoGenesis' physical mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The company's listed phone number is (916) 858-5100 and its investor relations email address is [email protected] The official website for ThermoGenesis is www.thermogenesis.com. Learn More about contacing ThermoGenesis investor relations.